This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pinski, J. Articles by Schally, A. V. Search for Related Content PubMed PubMed Citation Articles by Pinski, J. Articles by Schally, A. V.

Inhibitory Effects of Somatostatin Analogue RC-160 and Bombesin/Gastrin-releasing Peptide Antagonist RC-3095 on the Growth of the Androgen-independent Dunning R-3327-AT-1 Rat Prostate Cancer¹

Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana 70146, and Section of Experimental Medicine, Department of Medicine, Tulane University Medical School, New Orleans, Louisiana 70112

² To whom requests for reprints should be addressed, at Veterans Affairs Medical Center, 1601 Perdido Street, New Orleans, LA 70146.

The effects of somatostatin analogue RC-160 and bombesin/gastrin releasing-peptide (GRP) antagonist RC-3095 were evaluated in Copenhagen rats bearing the anaplastic, androgen-independent Dunning R3327-AT-1 prostatic adenocarcinoma. In the first experiment, RC-160 was given in the form of microcapsules releasing 60 µg/day/rat. RC-3095 was administered from implanted Alzet osmotic minipumps liberating 100 µg/day/rat. After 32 days, tumor volumes and weights were significantly reduced by RC-160 as compared with the control group. Tumor doubling time in rats treated with RC-160 was significantly longer than in controls. Bombesin/GRP antagonist RC-3095 also significantly reduced tumor volume after 7 days of treatment, but after 18 days the inhibition in tumor volume was no longer significant. Tumor growth was not suppressed by castration. In the second experiment, 3-mm³ fragments of Dunning R-3327-AT-1 tumor were implanted orthotopically into the prostates of Copenhagen rats in order to evaluate the survival time of animals bearing this cancer during treatment with RC-160 released from Alzet osmotic minipumps at a dose of 100 µg/day/rat. Treatment with RC-160 significantly (P < 0.05) prolonged the mean survival time of rats by 5.3 days as compared to control animals. In both experiments, therapy with RC-160 significantly decreased serum growth hormone or insulin-like growth factor I levels. In the first experiment, receptor assays on R-3327-AT-1 tumor membranes showed high affinity binding sites for somatostatin, bombesin, and epidermal growth factor. At the end of the treatment, receptors for epidermal growth factor were significantly down-regulated by treatment with RC-160 but not with RC-3095. The binding capacity of bombesin receptors was reduced to nondetectable levels after the treatment with RC-3095. In cell cultures, high affinity binding sites for bombesin/GRP were found on intact Dunning R-3327-AT-1 cells, but receptors for somatostatin could not be detected. Proliferation of the AT-1 cell line was significantly inhibited by antagonist RC-3095. However, no effect on tumor cell growth in vitro was observed with analogue RC-160. Our results demonstrate that somatostatin analogue RC-160 and bombesin/GRP antagonist RC-3095 can inhibit the growth of the androgen-independent Dunning R-3327-AT-1 prostatic cancer in rats, although the remission produced by RC-3095 may be of short duration due to a down-regulation of bombesin receptors. Our work suggests the merit of further investigation as to whether these analogues can induce a possible delay in relapse and prolong survival in prostate cancer.

¹ This work was supported by NIH Grant CA 40003 and the Medical Research Services of the Veterans Affairs, all to A. V. S. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official view of the National Cancer Institute.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/26/93. Accepted 10/29/93.

This article has been cited by other articles:

				X. Zhang, W. Cai, F. Cao, E. Schreibmann, Y. Wu, J. C. Wu, L. Xing, and X. Chen 18F-Labeled Bombesin Analogs for Targeting GRP Receptor-Expressing Prostate Cancer J. Nucl. Med., March 1, 2006; 47(3): 492 - 501. [Abstract] [Full Text] [PDF]

				R. P. Thomas, M. R. Hellmich, C. M. Townsend Jr., and B. M. Evers Role of Gastrointestinal Hormones in the Proliferation of Normal and Neoplastic Tissues Endocr. Rev., October 1, 2003; 24(5): 571 - 599. [Abstract] [Full Text] [PDF]

				L. Levine, J. A. Lucci III, B. Pazdrak, J.-Z. Cheng, Y.-S. Guo, C. M. Townsend Jr., and M. R. Hellmich Bombesin Stimulates Nuclear Factor {kappa}B Activation and Expression of Proangiogenic Factors in Prostate Cancer Cells Cancer Res., July 1, 2003; 63(13): 3495 - 3502. [Abstract] [Full Text] [PDF]

				P. D. Zapata, R. M. Ropero, A. M. Valencia, L. Buscail, J. I. Lopez, R. M. Martin-Orozco, J. C. Prieto, J. Angulo, C. Susini, P. Lopez-Ruiz, et al. Autocrine Regulation of Human Prostate Carcinoma Cell Proliferation by Somatostatin through the Modulation of the SH2 Domain Containing Protein Tyrosine Phosphatase (SHP)-1 J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 915 - 926. [Abstract] [Full Text] [PDF]

				G. Halmos, A. V. Schally, B. Sun, R. Davis, D. G. Bostwick, and A. Plonowski High Expression of Somatostatin Receptors and Messenger Ribonucleic Acid for Its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2564 - 2571. [Abstract] [Full Text]

				D. L. Livant, R. K. Brabec, K. J. Pienta, D. L. Allen, K. Kurachi, S. Markwart, and A. Upadhyaya Anti-invasive, Antitumorigenic, and Antimetastatic Activities of the PHSCN Sequence in Prostate Carcinoma Cancer Res., January 1, 2000; 60(2): 309 - 320. [Abstract] [Full Text]

				M. Gugger and J. C. Reubi Gastrin-Releasing Peptide Receptors in Non-Neoplastic and Neoplastic Human Breast Am. J. Pathol., December 1, 1999; 155(6): 2067 - 2076. [Abstract] [Full Text] [PDF]

				M. E. Cox, P. D. Deeble, S. Lakhani, and S. J. Parsons Acquisition of Neuroendocrine Characteristics by Prostate Tumor Cells Is Reversible: Implications for Prostate Cancer Progression Cancer Res., August 1, 1999; 59(15): 3821 - 3830. [Abstract] [Full Text] [PDF]

				R. Markwalder and J. C. Reubi Gastrin-releasing Peptide Receptors in the Human Prostate: Relation to Neoplastic Transformation Cancer Res., March 1, 1999; 59(5): 1152 - 1159. [Abstract] [Full Text] [PDF]

				A. Nagy, A. V. Schally, G. Halmos, P. Armatis, R.-Z. Cai, V. Csernus, M. Kovacs, M. Koppan, K. Szepeshazi, and Z. Kahan Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin PNAS, February 17, 1998; 95(4): 1794 - 1799. [Abstract] [Full Text] [PDF]

				G. Halmos and A. V. Schally Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095 PNAS, February 4, 1997; 94(3): 956 - 960. [Abstract] [Full Text] [PDF]

				A. Nagy, P. Armatis, R.-Z. Cai, K. Szepeshazi, G. Halmos, and A. V. Schally Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin PNAS, January 21, 1997; 94(2): 652 - 656. [Abstract] [Full Text] [PDF]

				M. J. Seckl, T. Higgins, and E. Rozengurt [D-Arg1,D-Trp5,7,9,Leu11]Substance P Coordinately and Reversibly Inhibits Bombesin- and Vasopressin-induced Signal Transduction Pathways in Swiss 3T3 Cells J. Biol. Chem., November 15, 1996; 271(46): 29453 - 29460. [Abstract] [Full Text] [PDF]